Determination of HIV Drug Resistance Among Children and Mothers Enrolled in Progr
Determination of HIV Drug Resistance Among Children and Mothers Enrolled in Progr
批准号:
8460402
负责人:
ACHIANGIA PATRICK NJUKENG
金额:
$40.77万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-30 至 2015-09-29
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract / Summary.
In Cameroon the HIV epidemic is generalized with an estimated prevalence of 5.1%, and
characterized by a very high genetic diversity. Indeed, to date the epidemic is driven by all HIV
subtypes including circulating recombinant forms (CRF), unique recombinant forms (URF), and
highly divergent strains such as groups O, and N and P. The impact of the high diversity on the
emergence of HIV drug resistance in Cameroon has not been well studied. In 2010, the coverage
of the PMTCT was 22.2% with 16.0% of infected children receiving antiretroviral treatment
nationwide. Limited studies in Cameroon reported primary resistance-associated mutations
among antiretroviral therapy (ART) drug-na¿ve persons, mainly to reverse transcriptase (RT) and
protease inhibitors. The Cameroon Baptist Convention Health Board (CBCHB) currently
supports 427 sites all over the country for the Prevention of Mother-to-Child Transmission
(PMTCT) program, of which 240 are government facilities. To date, CBCHB has counseled 450,
231 women and tested 428, 370 (95.1%) at these facilities (with an HIV prevalence of 10.7%).
Thanks largely to the CBCHB efforts, maternal and infant ART uptake rates have increased in
Cameroon from 37.7% in 2000 to 96.6% in 2009. The goal of this study is to determine the
prevalence of drug-resistant HIV among children < 18 months of age, and also evaluate the
impact of the enormous HIV genetic diversity on the occurrence of drug-resistant mutations in
PMTCT programs in Cameroon. Leftover dried blot spot specimens collected originally for early
infant diagnosis will be used in this study. The outcome of this study will assist decision-making
on first-line antiretroviral drug regimens for the PMTCT program in Cameroon and will provide
a better understanding of the association of the extensive HIV genetic diversity and occurrence
of resistant mutations. It will also contribute to the global effort to respond to the emergence of
HIV drug resistance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GH12-008, Cameroon, Determination of HIV Drug Resistance Among Children and Mothers Enrolled in Progr
-
批准号:8827179
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2013
-
负责人:ACHIANGIA PATRICK NJUKENG
-
依托单位:
GH12-008, Cameroon, Determination of HIV Drug Resistance Among Children and Mothers Enrolled in Progr
-
批准号:9071613
-
项目类别:
-
资助金额:$62.73万
-
财政年份:2013
-
负责人:ACHIANGIA PATRICK NJUKENG
-
依托单位:
国内基金
海外基金
登录
查看更多内容
人类免疫缺陷病毒(HIV)总核酸检测试剂盒
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:尹富君
-
依托单位:
HIV相关肺癌免疫微环境中关键免疫细胞亚群的功能特征与调控机制研究
-
批准号:2026JJ81995
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:田中秋
-
依托单位:
基于深度测序与SNV 芯片的HIV重复感染与毒株重组机制研究
-
批准号:2026JJ81281
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:徐艳
-
依托单位:
PGT123中和抗体修饰的工程化载肽囊泡疫苗通过诱导CD4+ T细胞极化在抗HIV感染中的应用和机制研究
-
批准号:JCZRQNB202600778
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
HIV相关血管早衰的免疫炎症机制及基于循环生物标志物的风险评估模型构建
-
批准号:2026JJ80647
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:关艳丽
-
依托单位:
基于病人旅程地图的HIV/AIDS患者双轨调适策略的混合性研究
-
批准号:2026JJ81431
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:夏友
-
依托单位:
基于NASBA-侧向层析联用的HIV-1 RNA检测方法构建及其扩增-识别耦合机制研究
-
批准号:JCZRLH202601701
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
HIV-1低病毒血症患者储存库活性与耐药突变评价体系的临床应用研究
-
批准号:2026JJ30181
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:陈钟
-
依托单位:
HIV介导树突状细胞线粒体损伤通过PD-L1通路促进潜伏结核激活的机制研究
-
批准号:2026JJ82503
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:李榜龙
-
依托单位:
基于分子-社会网络的成渝地区MSM人群HIV感染风险识别及协同管理机
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:谭天宇
-
依托单位: